Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pozen posts positive PN 400 results

Executive Summary

Patients taking Pozen's PN 400 have statistically significantly fewer endoscopically confirmed gastric ulcers than those taking enteric-coated naproxen in a six-month Phase III trial, the firm says Dec. 3. PN 400, a fixed-dose combination of the NSAID naproxen (500 mg) and proton pump inhibitor esomeprazole (20 mg), is being developed under a Special Protocol Assessment with FDA. However, FDA is re-evaluating the use of endoscopy to detect reduction of gastric ulcers as an endpoint and plans a meeting in first quarter 2009 to discuss the issue (1"The Pink Sheet," Nov. 17, 2008, p. 31). Pozen is partnered with AstraZeneca in development of the drug

You may also be interested in...

FDA Raising Approval Bar For NSAID/PPI Combos; Endpoints Under Review

FDA is considering changes to the approval process for NSAID and proton pump inhibitor combination products that may result in the agency prohibiting the use of endoscopic gastric ulcer reduction to support a gastroprotective marketing claim

Vaccine Experts Inject Realism Into US Gov't's COVID-19 Timeline

The Trump administration says a COVID-19 vaccine could be available in as little as 12 months, but most experts think that is overpromising unless safety or efficacy standards are sacrificed. Many are urging pivotal studies that look at clinical outcomes, not surrogates, for US FDA approval. 

Trump Pushes Back On OIG Report That Hospitals Want Feds To Better Police Resources, Relax Regs

When asked about an inspector general report that found hospitals are struggling with tests and resources, and are looking to the federal government to help facilitate more efficient distribution of medical devices to fight the COVID-19 crisis, President Trump attacked the report as a political hit from an Obama holdover.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts